Targeted therapies for Myeloproliferative Neoplasms MPNs

Abstract The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment in the treatment of MPNs, representing the first targeted treatment in this field. Despite a […]

Seven Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis

Click here for link to original publication. Note: At the bottom of each PDF page, be sure to click on the arrow (bottom left corner) to proceed to the next page. Copyright: c2016 Skov et al.  This is an open source article distributed under the terms of the creative commons attribution license, which permits unrestricted […]

 
error: Content is protected !